Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week High – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $27.13 and last traded at $26.8390, with a volume of 92718 shares trading hands. The stock had previously closed at $26.50.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on DYN shares. Cantor Fitzgerald assumed coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating for the company. Royal Bank Of Canada lifted their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. TD Cowen started coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Finally, Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.42.

Dyne Therapeutics Trading Up 1.1%

The stock’s fifty day simple moving average is $22.15 and its two-hundred day simple moving average is $19.26. The firm has a market cap of $5.00 billion, a PE ratio of -8.01 and a beta of 1.07. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.37 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 480,240 shares of Dyne Therapeutics stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $22.79, for a total value of $10,944,669.60. Following the completion of the transaction, the director owned 875,912 shares of the company’s stock, valued at $19,962,034.48. The trade was a 35.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner purchased 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $17.12 per share, for a total transaction of $42,800.00. Following the purchase, the director owned 18,000 shares in the company, valued at $308,160. This represents a 16.13% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 9,000 shares of company stock worth $156,800 and sold 1,558,819 shares worth $34,385,234. 9.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after buying an additional 14,727,667 shares during the last quarter. BlackRock Inc. bought a new position in Dyne Therapeutics in the 2nd quarter valued at approximately $275,500,000. Vanguard Group Inc. boosted its stake in Dyne Therapeutics by 14.9% during the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after purchasing an additional 1,455,151 shares during the last quarter. State Street Corp boosted its stake in Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after purchasing an additional 1,423,828 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after purchasing an additional 1,618,000 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.